In recent years, researchers have been interested in neuroprotective therapies as a cutting-edge therapeutic strategy to treat neurodegenerative disorders by shielding the brain system from harmful events. Millions of individuals worldwide suffer from glaucoma, an ocular neurodegenerative disease characterized by gradual excavation of the optic nerve head, retinal axonal damage, and consequent visual loss. The pathology’s molecular cause is still mostly unknown, and the current treatments are not able to alter the disease’s natural progression. Thus, the modern approach to treating glaucoma consists of prescribing medications with neuroprotective properties, in line with the treatment strategy suggested for other neurodegenerative diseases. For this reason, several naturally derived compounds, including nicotinamide and citicoline, have been studied throughout time to try to improve glaucoma management by exploiting their neuroprotective properties. The purpose of this review is to examine the naturally derived compounds that are currently utilized in clinical practice for neuroprotection in glaucomatous patients based on scientific data, emphasizing these compounds’ pivotal mechanism of action as well as their proven therapeutic and neuroprotective benefits.

The majority of neurodegenerative eye disorders occur with aging and significantly impair quality of life. Age-related macular degeneration (AMD) is the third most common cause of visual impairment and blindness worldwide. One of the most important elements in the pathophysiology of neurodegenerative eye disease is certainly oxidative stress, with neuroinflammation and ocular ischemia which may also be significant factors. Antioxidants, either by food or oral supplementation, may be able to mitigate the deleterious effects of reactive oxygen species that build as a result of oxidative stress, ischemia, and inflammation. Over the past few decades, a number of research works examining the potential adjuvant impact of antioxidants in AMD have been published. In fact, there is not only more and more interest in already known molecules but also in new molecules that can help clinicians in the management of this complex multifactorial disease, such as astaxanthin and melatonin. However, while some studies showed encouraging outcomes, others were conflicting. In addition, more and more attention is also being paid to nutrition, considered a pivotal key point, especially to prevent AMD. For this reason, the purpose of this review is to analyze the main antioxidant molecules currently used as oral supplements for AMD treatment, as well as the role of diet and food intake in this ocular disease, to better understand how all these factors can improve the clinical management of AMD patients.

Globally, diabetic retinopathy (DR) and diabetic macular edema (DME) are the leading causes of visual loss in working people. Current treatment approaches mostly target proliferative DR and DME, such as intravitreal injections of antivascular endothelial growth factor agents and laser photocoagulation. Before DR progresses into the more severe, sight‐threatening proliferative stage, patients with early stages of the disease must get early and appropriate care. It has been suggested that nutraceuticals, which are natural functional foods with minimal adverse effects, may help diabetic patients with DR and DME. Several in vitro and in vivo studies were carried out over the last years, showing the potential benefits of several nutraceuticals in DR due to their neuroprotective, vasoprotective, anti‐inflammatory, and antioxidant properties. Although most of the research is restricted to animal models and many nutraceuticals have low bioavailability, these compounds may adjuvate and implement conventional DR therapies. The purpose of this review is (i) to summarize the complex pathophysiology underlying DR and DME and (ii) to examine the main natural‐derived molecules and dietary habits that can assist conventional therapies for the clinical management of DR and DME.

Background: Colorectal cancer (CRC) risk is influenced by diet. Carotenoids are naturally occurring pigments primarily found in fruits and vegetables. Their potential chemopreventive properties are due to antioxidant, antimutagenic, and antiproliferative characteristics. Objectives: We investigated dietary carotenoid intakes (α-carotene, β-carotene, β-cryptoxanthin, lycopene, lutein+zeaxanthin, and total carotenoids) in relation to CRC risk. Methods: We used data from a case-control study on CRC conducted in Italy, which included 1953 histologically confirmed incident cases of CRC and 4154 controls. For each subject, carotenoid intake was estimated through a reproducible and valid food frequency questionnaire, using an Italian food composition database. Odds ratios (OR) and the corresponding 95% confidence intervals (95% CI) of CRC for the highest versus the lowest quintiles of carotenoid intakes were computed through multiple logistic regression models, including terms for total energy intake and other selected confounding factors. Results: The OR of CRC for the highest versus the lowest quintile was 0.72 (95% CI = 0.60–0.87) for α-carotene, 0.60 (95% CI = 0.49–0.73) for β-carotene, 0.83 (95% CI = 0.69–0.99) for β-cryptoxanthin, 0.64 (95% CI = 0.53–0.78) for lutein+zeaxanthin, and 0.59 (95% CI = 0.48–0.73) for total carotenoids, with significant trends across quintiles. No significant association was found for lycopene. Conclusions: Our findings indicate an inverse association between total and selected carotenoids and CRC risk.

The worldwide burden of visual impairment is mostly attributed to ocular diseases, which include alterations of the retina, optic nerve, cornea, and ocular surface. Despite advances in medicine, the prevention and management of these conditions remain challenging, driving ongoing research into novel bioactive compounds. Among these, polyphenols—an assorted group of plant-derived compounds abundant in the human diet—have attracted significant attention due to their potential antioxidant, anti-inflammatory, and immunomodulatory properties. Increasing evidence suggests that polyphenols may help counteract oxidative stress and modulate pathways involved in ocular pathologies, assisting the conventional therapeutic strategies. This narrative review aims to analyze the current evidence about the potential therapeutic effects of the main polyphenols (e.g., curcumin, resveratrol, epigallocatechin gallate) currently recognized for the management of ocular diseases.

Background: Plant-based diets are recommended in guidelines for the prevention of cancer and cardiometabolic diseases, which remain major causes of death in breast cancer survivors (BCS). Since not all plant foods are healthy, we calculated the plant-based dietary index (PDI), healthy (hPDI) and unhealthy (uPDI), and their associations with cardiometabolic targets in BCS. Methods: Baseline dietary and cardiometabolic data were derived from 492 (median age 51, IQR 46–59) female BCS participating in a multicentric lifestyle trial conducted in Italy. Dietary data were collected with 7-day food records. PDI, hPDI, and uPDI were calculated by assigning positive scores to all plant foods, healthy plant foods or less healthy plant foods, respectively, as defined by the literature (scores ranged from 18 to 90). Using logistic or multinomial regression models, we estimated the odds ratios (OR) and the corresponding 95% confidence intervals (CI) between PDIs and cardiometabolic risk factors. Results: The OR of being obese (BMI ≥ 30 Kg/m²) was 0.47 (95%CI: 0.29–0.77), 0.37 (95%CI: 0.22–0.61) and 1.38 (95%CI: 0.83–2.28) with higher PDI, hPDI and uPDI, respectively. The OR of having a large waist circumference (≥88 cm) was 0.64 (95%CI: 0.42–1.00) with higher hPDI. The OR for hypercholesterolemia (≥200 mg/dL) was 1.80 (95%CI: 1.16–2.78) with higher uPDI. The ORs of hypertriglyceridemia (≥150 mg/dL) and metabolic syndrome were 0.38 (95%CI: 0.20–0.71) and 0.59 (95%CI: 0.35–0.97), respectively, with higher PDI. No other significant association was observed. Conclusions: Maintaining cardiometabolic risk factors within normal ranges is clinically relevant in BCS, and this may be more likely when a plant-based diet is consumed, especially if low in unhealthy plant foods.